Gameto key facts
as of Oct 2026- Operator of a biotechnology company intended to solve diseases of the female reproductive system.
- Gameto is valued at approximately $243.0M as of Oct 2026, set at its later-stage round, Aug 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $127.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($44.0M) in Aug 2025.
- Notable investors include FJ Labs, Insight Partners (New York), Gaingels, RA Capital Management, Lux Capital — 49 tracked in total.
- Gameto has filed 2 Form Ds with the SEC since 2024, most recently Aug 2025 ($44.0M sold to 22 investors).
- Status: Privately Held (backing).
Valued at $243.0M at its later-stage round, Aug 2025. Nothing has traded since.
- ·The complete investor list: 49 names
- ·Watch Gameto: the Monday email on marks, rounds and moves
Gameto funding rounds
2 roundsWho backs Gameto
49+Gameto valuation
Gameto was valued at $243 million at its later-stage round in Aug 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Gameto raised?
Gameto has raised $127 million in total; 2 of its rounds are on record. The largest on record was a $44 million Series C in Aug 2025.
Gameto has filed 2 Form Ds with the SEC since 2024, most recently in Aug 2025 ($44 million sold to 22 investors).
Gameto investors
49 investors are on record for Gameto, including FJ Labs, Insight Partners (New York), Gaingels and RA Capital Management. By type, the record holds 14 venture capital firms, 5 family offices and 2 private equity firms. The Series C in Aug 2025 drew 11 investors.
Comparable companies
Comparable biotechnology names by valuation on PrivateMarketView: Ansa Biotechnologies ($269 million), Ambros Therapeutics ($250 million) and Antheia ($240 million).
About Gameto
Operator of a biotechnology company intended to solve diseases of the female reproductive system. The company's platform uses proprietary combinations of transcription factors to generate engineered ovarian cell lines that mimic the functions of endogenous cells, producing and responding to all hormones, enabling women to solve the problem of accelerated ovarian aging.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2020
- Employees
- 47
- Website
- gametogen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.